Sanofi Shs Sponsored American Deposit Receipt Repr 1/2 Sh $52.34

up +0.67


17/4/2014 06:40 PM  |  NYSE : SNY  
Industries : Drugs / Drugs - Generic
Get Trend Analysis Icon Get SNY Trend Analysis - it has underperformed the S&P 500 by 20%

Partner Headlines

  1. Oakmark's Bill Nygren Discusses Financials, Favorite Stocks

    GuruFocus
  2. From Oakmark’s Market Beaters: Value + Income

    YCharts
  3. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest ...

    Benzinga
  4. Cholesterol drug meets goal

    IBD
  5. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  6. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  7. US Stock Futures Rise; GDP, Jobless Claims Data In Focus

    Benzinga
  8. Sanofi's Getting Back in the Game

    GuruFocus
  9. Market Wrap For March 25: Markets Snap Two-Day Losing Steak On Confidence ...

    Benzinga
  10. Novo Nordisk Upgraded to 'Buy'

    FoxBusiness
  11. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  12. Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks

    GuruFocus
  13. Regeneron falls on FDA probe

    IBD
  14. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  15. Warren Buffett Shows Changes to International Stocks: Tesco, Munich Re, ...

    GuruFocus
  16. Top Three Holdings of a Top Investment Advisory Firm

    GuruFocus
  17. Regeneron CEO Sees Surge

    IBD
  18. Regeneron Pipeline Could Be The Big Story In 2014

    IBD
  19. Eli Lilly up on lung cancer trial

    IBD
  20. Lilly Drug Ramucirumab Boosts Lung Cancer Survival

    IBD
  21. Francis Chou's Top Holdings at Year End

    GuruFocus
  22. Regeneron Longer-Term Growth Prospects Boosts Stock

    IBD
  23. Regeneron To Guide 2014 As Eylea Continues To Shine

    IBD
  24. Stock Futures Up, Off Highs; Coke Deal Boosts Green Mountain

    IBD
  25. Biogen MS Drug Tecfidera Outperforms; Outlook Light

    IBD
  26. Zealand Announces Advance by Sanofi of LixiLan, the Single Injection Lyxumia(R)/Lantus(R) ...

    Benzinga
  27. Illumina, Regeneron, Intuitive Q4 Results Impress

    IBD
  28. Benzinga's M&A Chatter for Monday January 13, 2014

    Benzinga
  29. Stocks Futures Mildly Lower; Lululemon, Ascena Pare Guidance

    IBD
  30. US Stock Futures Fall Ahead Of Federal Budget

    Benzinga
  31. Genzyme, Alnylam Expand Collaboration on Rare Genetic Diseases

    Benzinga
  32. Correction Protection: Better Metric Finds Value

    YCharts
  33. Genzyme drug rejected in U.S.

    IBD
  34. Stocks To Watch For December 30, 2013

    Benzinga
  35. Warren Buffett's International Stocks: Update 2013

    GuruFocus
  36. ObamaCare = Drug Maker Assistance Act

    YCharts
  37. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  38. Bristol-Myers' Diabetes Sale Sharpens Biopharma Focus

    IBD
  39. AstraZeneca Buys Out Bristol-Myers' Diabetes Business

    IBD
  40. Pharma’s Pay-to-Delay Deals Targeted Again

    YCharts
  41. Pfizer’s Great Hope Xeljanz: More Bad News

    YCharts
  42. Genzyme's Lemtrada Approved in Canada for Treatment of MS

    Benzinga
  43. Top Guru-Bought European Stocks of the Third Quarter

    GuruFocus
  44. VIVUS Announces License and Commercialization Agreement With Sanofi for ...

    Benzinga
  45. FDA Asks Meat Industry to Stop Using Antibiotics in Animal Feed

    FoxBusiness
  46. FDA Grants Priority Review for Genzyme's Cerdelga for Gaucher Disease

    Benzinga
  47. Europe Cracks Down on Pharma Pay-to-Delay Deals

    YCharts
  48. Pfizer - Key Reasons to Long This Biopharmaceutical Giant

    GuruFocus
  49. Pharma Stocks: R&D Spend and Returns

    YCharts
  50. After Top-Seller Remicade: Analysis of J&J’s Future

    YCharts
Trading Center